Journal: Scientific Reports

Article Title: CD146 + interstitial cells contribute to the dystrophic skeletal muscle phenotype in vitro

doi: 10.1038/s41598-026-38311-2

Figure Lengend Snippet: Gene expression analysis of CD146 + cells isolated from WT and mdx mice. ( A ) Expression levels of pericyte markers (Mcam, Alp , Pdgfrb) , and FAP marker (Pdgfra) evaluated directly after sorting CD146 + cells (dots),and after 5 days of in vitro cultures (triangles). ( B ) Expression levels of pericyte marker (Cspg4),progenitor cell marker (Nes), FAP marker (Pdgfra) and satellite cell/myoblast markers (Peg3, Pax7 , Myod) evaluated after 5 days of in vitro culture. Data were visualized on scatter plots with bars, where each dot represents one independent biological replicate, and compared using the t-test. Differences were considered statistically significant when p < 0.05 (marked with asterisks,* p < 0.05; ** p < 0.005; *** p < 0.001; **** p < 0.0001). Finally, we observed that expanded for 5 days in vitro mdx CD146 + cells had lower expression levels of all tested myogenic markers, including Peg3 , Pax7 , and Myod ,compared to WT CD146 + cells, ( Fig. 2B ). It should be noted , however ,that Pax7 expression levels in WT CD146 + cells remain very low overall, and Pax7 protein is not detectable in CD146 + cells,as we have previously demonstrated. 15, 16.

Article Snippet: RNA-based cDNA was synthesized using the RevertAid First-Strand cDNA synthesizer kit (ThermoFisher), according to the manufacturer’s protocol, under the following conditions: 25 ° C for 5 min, 42 °C for 90 min, and 70 ° C for 5 min. mRNA levels were evaluated using quantitative real-time PCR analysis (qRT-PCR) with TaqMan assays (ThermoFisher) for the following genes: Mcam (Mm00522397_m1), Alp (Mm00475834_m1), Pdgfrb (Mm01262487_m1), Cspg4 (encoding Ng2, Mm0050725_m1), Nes (Mm00450205_m1), Pdgfra (Mm00440701_m1), Peg3 (Mm01337379_m1), Pax7 (Mm01354484_m1), Myod (Mm00521984_m1).

Techniques: Gene Expression, Isolation, Expressing, Marker, In Vitro

Journal: ACS Omega

Article Title: Site-Specific Glycan Conjugation Improves Stability and Efficacy of an Antibody–Drug Conjugates Bearing DXd as a Cytotoxic Payload

doi: 10.1021/acsomega.5c10898

Figure Lengend Snippet: Preparation Scheme of Glycan-Conjugated ADC and Payload Structures. (i) Inherent Heterogeneous Glycan Removal by ENGase. ENGase Cleaves the Bond Between the β-1,4-Glycosidic Linkage Within the N,N ′-Diacetylchitobiose Core. Heterogeneous Regions are Indicated in Parentheses; (ii) An Azide-Carrying Glycan 4 was Added via the ENGase Mutant; (iii) Biorthogonal Reaction Between the Azide Group and DBCO. Payload Structure: DBCO-PEG 3 -VC-PAB-MMAE 5 ; DBCO-PEG 4 -GGFG-DXd 6 ; Trasuzumab-SG-PEG 3 -VC-PAB-MMAE 7 ; Trasuzumab-SG-PEG 4 -GGFG-DXd 8

Article Snippet: DBCO-PEG 3 -VC-PAB-MMAE 5 and DBCO-PEG 4 -Gly-Gly-Phe-Gly-DXd 6 were purchased from MedChemExpress (Monmouth Junction, NJ, USA) and Levena Biopharma (San Diego, CA, USA), respectively.

Techniques: Glycoproteomics, Mutagenesis